Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer’s disease

References

• Alzheimer’s Association2013 Alzheimer’s Disease Facts and FiguresWashington, DCAlzheimer’s Association2013 Available from: http://www.alz.org/alzheimers_disease_facts_and_figures.aspAccessed March 25, 2013
   Google Scholar
• LopezOLBeckerJTWisniewskiSSaxtonJKauferDIDeKoskySTCholinesterase inhibitor treatment alters the natural history of Alzheimer’s diseaseJ Neurol Neurosurg Psychiatry200272331031411861686
   PubMed Web of Science ®Google Scholar
• AtriAShaughnessyLWLocascioJJGrowdonJHLong-term course and effectiveness of combination therapy in Alzheimer diseaseAlzheimer Dis Assoc Disord200822320922118580597
   PubMed Web of Science ®Google Scholar
• RogersSLDoodyRSMohsRCFriedhoffLTDonepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study GroupArch Intern Med19981589102110319588436
   PubMed Web of Science ®Google Scholar
• FeldmanHHPirttilaTDartiguesJFAnalyses of mortality risk in patients with dementia treated with galantamineActa Neurol Scand20091191223118518863
   PubMed Web of Science ®Google Scholar
• DoodyRSDunnJKClarkCMChronic donepezil treatment is associated with slowed cognitive decline in Alzheimer’s diseaseDement Geriatr Cogn Disord200112429530011351141
   PubMed Web of Science ®Google Scholar
• KavanaghSVan BaelenBSchäubleBLong-term effects of galantamine on cognitive function in Alzheimer’s disease: a large-scale international retrospective studyJ Alzheimers Dis201127352153021891871
   PubMed Web of Science ®Google Scholar
• NordströmPReligaDWimoAWinbladBEriksdotterMThe use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s diseaseEur Heart J201334332585259123735859
   PubMed Web of Science ®Google Scholar
• RountreeSDChanWPavlikVNDarbyEJDoodyRSFactors that influence survival in a probable Alzheimer disease cohortAlzheimers Res Ther2012431622594761
   PubMed Web of Science ®Google Scholar
• GeertsHGrossbergGTPharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer’s diseaseJ Clin Pharmacol2006467 Suppl 18S16S16809810
   PubMed Web of Science ®Google Scholar
• Razadyne ER® and Razadyne® (galantamine hydrobromide) extended-release tablets, tablets, and oral solution [prescribing information]Titusville, NJJanssen Pharmaceuticals, Inc2013 Available from: http://www.razadyneer360.com/full-prescribing-information.htmlAccessed November 21, 2013
   Google Scholar
• SmallGErkinjunttiTKurzALilienfeldSGalantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer’s disease with cerebrovascular diseaseCNS Drugs2003171290591412962529
   PubMed Web of Science ®Google Scholar
• RaskindMAPeskindERWesselTYuanWGalantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study GroupNeurology200054122261226810881250
   PubMed Web of Science ®Google Scholar
• RockwoodKMintzerJTruyenLWesselTWilkinsonDEffects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trialJ Neurol Neurosurg Psychiatry200171558959511606667
   PubMed Web of Science ®Google Scholar
• TariotPNSolomonPRMorrisJCKershawPLilienfeldSDingCA 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study GroupNeurology200054122269227610881251
   PubMed Web of Science ®Google Scholar
• WilcockGKLilienfeldSGaensEEfficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: multicentre randomised controlled trial. Galantamine International-1 Study GroupBMJ200032172741445144911110737
   PubMed Web of Science ®Google Scholar
• WinbladBGauthierSScintoLGAL-INT-11/18 Study GroupSafety and efficacy of galantamine in subjects with mild cognitive impairmentNeurology200870222024203518322263
   PubMed Web of Science ®Google Scholar
• McKhannGDrachmanDFolsteinMKatzmanRPriceDStadlanEMClinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s DiseaseNeurology19843479399446610841
   PubMed Web of Science ®Google Scholar
• FolsteinMFFolsteinSEMcHughPR“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinicianJ Psychiatr Res19751231891981202204
   PubMed Web of Science ®Google Scholar
• GélinasIGauthierLMcIntyreMGauthierSDevelopment of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementiaAm J Occup Ther199953547148110500855
   PubMed Web of Science ®Google Scholar
• PirttiläTWilcockGTruyenLDamarajuCVLong-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer’s disease: multicenter trialEur J Neurol2004111173474115525294
   PubMed Web of Science ®Google Scholar
• ScheltensPvan de PolLImpact commentaries. Atrophy of medial temporal lobes on MRI in “probable” Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlatesJ Neurol Neurosurg Psychiatry201283111038104022566596
   PubMed Web of Science ®Google Scholar
• Takada-TakatoriYKumeTSugimotoMNeuroprotective effects of galanthamine and tacrine against glutamate neurotoxicityEur J Pharmacol20065491–3192616996497
   PubMed Web of Science ®Google Scholar
• TakataKKitamuraYSaekiMGalantamine-induced amyloid-{beta} clearance mediated via stimulation of microglial nicotinic acetylcholine receptorsJ Biol Chem201028551401804019120947502
   PubMed Web of Science ®Google Scholar
• KiharaMKuboTImmunocytochemical localization of glutamate containing neurons in the ventrolateral medulla oblongata and the nucleus tractus solitarius of the ratJ Hirnforsch19913211131181687413
   PubMedGoogle Scholar
• MawuenyegaKGSigurdsonWOvodVDecreased clearance of CNS beta-amyloid in Alzheimer’s diseaseScience20103306012177421148344
   PubMed Web of Science ®Google Scholar
• BuissonBBertrandDOpen-channel blockers at the human alpha4beta2 neuronal nicotinic acetylcholine receptorMol Pharmacol19985335555639495824
   PubMed Web of Science ®Google Scholar
• AracavaYPereiraEFMaelickeAAlbuquerqueEXMemantine blocks alpha7* nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neuronsJ Pharmacol Exp Ther200531231195120515522999
   PubMed Web of Science ®Google Scholar
• HowardRMcShaneRLindesayJDonepezil and memantine for moderate-to-severe Alzheimer’s diseaseN Engl J Med20123661089390322397651
   PubMed Web of Science ®Google Scholar
• CourtneyCFarrellDGrayRAD2000 Collaborative GroupLong-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trialLancet200436394272105211515220031
   PubMed Web of Science ®Google Scholar